CD36-mediated uptake of oxidized LDL induces double-negative regulatory T cell ferroptosis in metabolic

Yunxiong Wei1, Yuan Jiang2, Jingjing Zhu2

  • 1Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Immunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Abstract

Insights

Oxidized low-density lipoprotein (oxLDL) impairs double negative T regulatory cells (DNT) in metabolic dysfunction-associated steatotic liver disease (MASLD). Targeting CD36 to prevent ferroptosis in DNT offers a potential MASLD therapy.

Area of Science:

  • Immunology
  • Hepatology
  • Metabolic Diseases

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) involves liver inflammation driven by metabolic alterations.
  • During MASLD progression, double negative T regulatory cells (DNT) exhibit reduced survival and immunosuppressive function, exacerbating liver inflammation.

Purpose of the Study:

  • To elucidate the mechanisms underlying DNT alterations during MASLD progression.
  • To investigate the role of oxidized low-density lipoprotein (oxLDL) in DNT dysfunction in MASLD.

Main Methods:

  • Correlated serum oxLDL levels with DNT in MASLD patients and mouse models.
  • Utilized transcriptome sequencing, flow cytometry, and CUT & TAG to explore oxLDL's effects on DNT survival and function.

Main Results:

  • Serum oxLDL negatively correlated with DNT survival and function in MASLD.
  • oxLDL upregulates CD36 expression in DNT via the NF-κB pathway, promoting oxLDL uptake, ferroptosis, and functional impairment.
  • Targeting CD36 mitigated ferroptosis and improved DNT immune regulation, enhancing therapeutic efficacy in MASLD mouse models.

Conclusions:

  • oxLDL diminishes DNT survival and immune regulatory capacity, compromising liver immune homeostasis in MASLD.
  • Targeting CD36 to inhibit ferroptosis in DNT presents a novel therapeutic strategy for MASLD.